Navigation Links
Low forms of cyclin E reduce breast cancer drug's effectiveness
Date:2/9/2010

l in breast cancer research.

The M. D. Anderson team hypothesized that ER+ breast cancer patients whose tumors express the LMW forms of cyclin E would be less responsive to treatment with an aromatase inhibitor. To test their hypothesis, the researchers exposed aromatase-overexpressing MCF-7/Ac1 breast cancer cells to the full-length form of cyclin E or to the LMW-E forms ("low forms").

"We found that we could negate the growth inhibitory effects of letrozole with the low forms of cyclin E but not with the wild-type cyclin E," said Keyomarsi, the study's senior author. "The mechanism behind this is that the low forms of cyclin E increase the activity of the cyclin E complex, and this complex is what mediates the negative effects."

CDK2 Inhibitor Restores Letrozole's Growth Inhibition

After confirming that the LMW forms of cyclin E suppress the anti-proliferative effects of letrozole, the researchers examined whether a CDK2 inhibitor could reverse the drug resistance in the unresponsive breast cancer cells.

"We challenged the aromatase-overexpressing cells with either the wild-type or the low forms of cyclin E and then treated them with the CDK2 inhibitor roscovitine," Keyomarsi said. "When we did that, we could kill all the cells."

The researchers also looked back at the results of another ongoing study from their group in which 128 ER+ breast cancer patients were treated with an aromatase inhibitor. "Of those, 100 expressed normal levels of wild-type cyclin E, and 28 overexpressed the low forms," Keyomarsi said. "When we looked at recurrence, three of the hundred with wild-type cyclin E had experienced a recurrence compared to four of the twenty-eight with the low forms. That in itself tells us there is a huge difference between the two groups of patients based on the pattern of expression of normal versus low forms of cyclin E."

Of the seven patients who had a recurrence, six had high levels of
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
2. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
3. Fat transforms vitamin C from good cop into bad cop
4. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
5. Care reforms raise concerns over patient access to GP services
6. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
7. Pro-Consumer Drug Safety Reforms Agreed to in Final FDA Bill; Should End Drug Industry Gaming of Safety System
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Ingenious Med Forms Multiple Billing Company Partnerships to Market Inpatient Practice Management Solutions
10. Governor Rendell Calls for Prompt Action on Prescription for Pennsylvania, Cover All Pennsylvanians Health Care Reforms
11. How Candida albicans transforms from its normally benign form into life-threatening form
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Low forms of cyclin E reduce breast cancer drug's effectiveness
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Researchers say they ... that develop into eggs and sperm. While this ... is the first time that these types of cells ... efficiently using human stem cells, according to the team ... creation of primordial germ cells is one of the ...
(Date:12/24/2014)... ladies, new fashionable outfits are necessary when heading into a ... Angeldress.co.uk has chosen some of their best dresses ... by launching a promotion on its cheap clothes and fashion ... off, like a cheap suit. , “All items are in ... are among the hottest items in the global market. They ...
(Date:12/24/2014)... Lauderdale, FL (PRWEB) December 24, 2014 There’s ... these days. With the Republican Party now in control of ... begins again for the Affordable Care Act. A lawsuit has ... that delays of certain provisions in the ACA have resulted ... (1) Also, a Supreme Court hearing will take place to ...
(Date:12/24/2014)... St. Louis, MO (PRWEB) December 24, 2014 ... Onder Law Firm announce an update to their website, ... information explains the difference between talcum powder class action ... provide weekly talcum powder and ovarian cancer updates at ... , “Talcum powder lawsuits for ovarian cancer claims are ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... hurt your child in the classroom, a new study finds. ... lagged behind by eighth grade, said researchers who reviewed questionnaires ... "The largest effects were found for the kids who reported ... assistant professor of human sciences at Ohio State University. "On ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:Can Fast Food Hinder Learning in Kids? 2
... W. M. Keck Foundation has awarded Arizona State University ... scientists led by Deirdre Meldrum, Ph.D., at the Biodesign ... three-dimensional (3D) imaging microscope, called a "Cell-CT" scanner, that ... living cells. This groundbreaking technology will allow researchers to ...
... help explain why African-Americans are twice as likely to be ... new study by Johns Hopkins researchers. The findings, if ... as easy as taking a cheap potassium supplement. ... taking potassium supplements," says Hsin-Chieh "Jessica" Yeh, Ph.D., an assistant ...
... , WEDNESDAY, March 2 (HealthDay News) -- Countering ... from mental illness, a new report says there,s actually no ... they often go without treatment that could prevent them from ... "pervasive, but mistaken, impression that young children do not develop ...
... HealthDay Reporter , TUESDAY, March 1 (HealthDay News) ... to increase the risk for breast cancer among postmenopausal ... found little or no connection between breast cancer and ... may be surfacing for the first time, experts noted. ...
... 18th Conference on Retroviruses and Opportunistic Infections is ... from February 27 through March 2. Day three of ... presentations from scientists supported by the National Institute of ... Institutes of Health. iPrEx Update , ...
... , Emory University experts predict that rates of depressive disorders ... In an editorial published in the March, 2011 issue of ... author Boadie Dunlop, MD, writes "Compared to women, many men ... protectors of their families. Failure to fulfill the role of ...
Cached Medicine News:Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 3Health News:Potassium levels possible key to racial disparity in Type 2 diabetes 2Health News:Even Tiny Tots May Develop Mental Health Problems 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 3Health News:CROI -- Day 3: Selected highlights of NIH-supported research 2Health News:Depressing future for men? 2
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... a clinical-stage company focused on commercialization of novel ... restatement of its exclusive international license agreement with ... technology related to monitoring drug therapy compliance.  The ... Sequella and UMB, addresses transdermal detection of a ...
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
Cached Medicine Technology:Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... (E1) is one of the three major ... and estriol. Estrone is produced primarily from ... or gonads [1,2]. In premenopausal adult women, ... by the ovary. In prepubertal children, men ...
... most abundant circulating estrogen in non-pregnant women ... Sulfate is a major metabolite of estradiol ... in blood [2,3]. In premenopausal women, estrone ... and estradiol, rising gradually during the follicular ...
Medicine Products: